Quotes of All Topics . Occasions . Authors
We need to ask ourselves: What use is our scientific endeavor and innovation when they are inaccessible to the people who need them the most? It is only when the benefits of research reach the person on the lowest rung of the economic ladder that it can be considered to have delivered true value.
In India, I personally believe yes, there is a clear fear of unknown; there's a lot of risk aversions in science and technology. They want predictability in everything they do, and it starts from people. It starts from investors. It starts from the regulators. You see that mindset across the society.
Unfortunately our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very-very strong balance sheet with huge value drivers at the end of it.
Unfortunately, our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very, very strong balance sheet with huge value drivers at the end of it.
I think, in terms of corporate philosophy, I've always believed that you've got to treat people in a very very egalitarian manner in the sense I like to treat people on a one-to-one basis. And I like people to take on a lot of responsibilities because I think with a sense of responsibility also comes a sense of purpose.
Being in a field like healthcare, for me, as someone who is basically on a mission to make a global impact in terms of affordable access to healthcare, I am very, very concerned about the fact that there are a large number of people in this world who need to have some access to basic rights, whether it is in education or healthcare.